Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma.

JAAD Case Rep · 2019 · PMC6804468 · PMID 31649970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In patients with metastatic melanoma, intralesional T-VEC therapy has only shown a positive trend of overall survival benefit, whereas the checkpoint inhibitors lead to a significant survival benefit. 5 Growing evidence suggests that intralesional T-VEC could synergize immune stimulation by checkpoint inhibitors.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.